Abstract-Although the presence of intracellular angiotensin II (Ang II) and of Ang II-binding sites has been reported, their roles in cell function have not been fully clarified. The purpose of the present study was to test the hypothesis that intracellular Ang II modifies voltage-operated Ca 2ϩ channels in vascular smooth muscle. Ca 2ϩ channel currents were recorded in guinea pig mesenteric arterial myocytes with the whole-cell patch-clamp method. Intracellular dialysis of Ang II increased the amplitudes of Ca 2ϩ channel current (133Ϯ9% of the control with 10 nmol/L Ang II, nϭ16). Concomitant dialysis of the Ang II type 1 receptor antagonist, CV-11974 (1 mol/L, nϭ11), but not the bath application of this drug, suppressed this Ang II action. In contrast, the dialysis of the Ang II type 2 receptor antagonist, PD123319 (1 mol/L, nϭ5), failed to affect the Ang II action. Dialysis of either a phospholipase C inhibitor (U-73122, 10 mol/L, nϭ5) or protein kinase C inhibitors (calphostin C, 100 nmol/L, nϭ5; protein kinase C inhibitor peptide- [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29][30][31][32][33][34][35][36], 1 mol/L, nϭ5) suppressed the Ang II action. Dialysis of KT5720 (100 nmol/L, nϭ5), an inhibitor of cAMP-dependent protein kinase, did not affect the Ang II action. Intracellular dialysis of angiotensin I (10 nmol/L) enhanced Ca 2ϩ channel currents (13 3Ϯ8%, nϭ6), which were sensitive to intracellular enalaprilat (1 mol/L, nϭ5) or CV-11974 (nϭ5). These results suggest that intracellular Ang II has a stimulating action on voltage-operated Ca 2ϩ channels in vascular smooth muscle, possibly through intracellular binding sites similar to the Ang II type 1 receptor, which are associated with phospholipase C and protein kinase C. 
L ocal renin-angiotensin systems in the heart, kidneys, and vascular wall play a pivotal role in the pathogenesis of hypertensive organ damage and atherosclerosis. 1, 2 Recent evidence suggests that angiotensin II (Ang II) and its generating system are present also inside the cell. [1] [2] [3] [4] [5] Most physiological actions of Ang II are mediated through Ang II receptors on the plasma membrane. However, soluble cytoplasmic Ang II-binding protein and nuclear Ang II-binding sites, which have different physicochemical properties from Ang II receptors at the plasma membrane, have been reported. 6 -11 The roles of intracellular Ang II and its binding sites in the cardiovascular system are not yet fully understood; however, several reports regarding this subject exist. An activation of nuclear Ang II receptors initiates the transcription of renin and angiotensinogen mRNA in liver cells. 11 An intracellular administration of Ang II reduces Ca 2ϩ currents in rat ventricular myocytes but increases these currents in hamster ventricular myocytes. 5, 12 Intracellular Ang II has also been shown to decrease the junctional conductance of cardiac muscles. 5 In cultured aortic muscle cells, microinjection of Ang II increases intracellular Ca 2ϩ concentration, as determined by Ca 2ϩ -sensitive dye. 13 Moreover, intracellular application of Ang II by the liposome method contracts the rat aorta. 14 In the above 2 studies of smooth muscle, the intracellular Ang II actions are abolished by a removal of extracellular Ca 2ϩ , suggesting that Ca 2ϩ influx from extracellular spaces could be responsible for these actions. However, the mechanism by which intracellular Ang II modifies intracellular Ca 2ϩ concentration and vascular tone has not been fully understood. In the present study, we dialyzed Ang II, Ang II receptor antagonists, and protein kinase inhibitors into the cell during the whole-cell patch-clamp experiments to assess the action of intracellular Ang II on voltage-operated Ca 2ϩ channels and its signal-transduction pathway in vascular smooth muscle cells.
Methods
Single smooth muscle cells were isolated from the small mesenteric arteries (diameter, Ͻ300 m) of guinea pigs (200 to 300 g) by collagenase treatment, as described previously. 15, 16 The study protocol was approved by the Committee of Ethics of Animal Experimentation, Faculty of Medicine, Kyushu University.
Conventional whole-cell patch-clamp methods were performed with a patch pipette through a voltage-clamp amplifier (Axopatch 1-D, Axon Instruments Inc), as previously described. 16, 17 Recording electrodes were made from Pyrex glass capillary tubing (resistance, 5 to 6 M⍀). Test command potentials of 10 mV with a duration of 50 ms were applied every 20 seconds from a holding potential of Ϫ80 mV, unless otherwise stated. Membrane currents were digitized with a sampling frequency of 5 to 10 kHz and stored in a personal computer system for subsequent analysis. The liquid junction potential of 10 mV was corrected. The leak and residual capacitive currents were subtracted by use of the P/4 protocol. The traces are shown after low-pass filtering at 1 kHz. All experiments were performed at room temperature (22°C to 24°C). Average value of the cell capacitance was 17.8Ϯ0.2 pF (nϭ52).
To isolate Ca 2ϩ channel currents, the pipette was filled with a high Cs ϩ solution of the following composition (mmol/L): CsCl 132.5, ATP-Na 2 3, GTP 0.1, MgCl 2 3, EGTA 10, and HEPES 10, pH 7.3 (titrated with CsOH). Ba 2ϩ ion was used as a carrier of Ca 2ϩ channel currents. The Ba 2ϩ -containing bath solution consisted of (mmol/L) BaCl 2 10, NaCl 150, glucose 5.4, and HEPES 5, pH 7.3 (titrated with NaOH).
Ang II and angiotensin I (Ang I) were purchased from Sigma Chemical Co. Nifedipine, protein kinase C (PKC) inhibitor peptide- [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] , calphostin C, and KT5720 were from Calbiochem. CV-11974, enalaprilat, and PD123319 were gifts from Takeda Pharmaceutical Co (Tokyo, Japan), Merck Co (West Point, Pa), and Parke-Davis Co (Ann Arbor, Mich), respectively.
The very tip of the recording pipette was filled with a drug-free solution (control solution), and the reminder of the pipette was filled with the drug-containing solution (test solution). In our preliminary experiments, a drug in the test solution diffuses and reaches the pipette tip Ϸ5 to 6 minutes after rupture of the patch membrane. For example, with the same pipette size (5 to 6 M⍀), ATP in the pipette solution stimulates Ca 2ϩ currents, or Cs ϩ solution in the pipette solution inhibits K ϩ currents 5 to 6 minutes after the membrane rupture. Because the amplitude of the Ca 2ϩ channel current reached a stable level Ϸ3 minutes after the membrane rupture, we evaluated the intracellular action of the drug by comparing the current at a certain time with that recorded at 3 minutes after the membrane rupture (as a control).
Data are given as meanϮSEM. Statistical significance was determined by ANOVA and then a post hoc test. Values of PϽ0.05 were considered statistically significant.
Results
Without Ang II in the pipette solution, the amplitude of Ca 2ϩ channel current reached a steady level at Ϸ3 minutes after achieving the whole-cell condition and did not apparently run down for up to 20 minutes ( Figure 1A ). 15, 16 When Ang II (10 nmol/L) was included in the test solution, the amplitudes of Ca 2ϩ channel currents continued to increase for 7 to 8 minutes ( Figure 1A ). This continuous increase in the amplitude of Ca 2ϩ channel currents was observed in the presence of Ang II at Ն1 nmol/L; however, the enhancement did not apparently differ among various Ang II concentrations (at 10 minutes: Figure 1B shows the effects of intracellular Ang II on the current-voltage relationship of the Ca 2ϩ channel currents. Intracellular Ang II enhanced the amplitude but did not apparently affect the shape of the current-voltage curve, although the enhancement was less evident at negative potentials. The major part of the Ca 2ϩ channel current in vascular muscle cells from the mesenteric artery was of the L type, which is sensitive to dihydropyridines, including nifedipine. 17, 18 However, nifedipine-insensitive Ca 2ϩ channels exist in small branches of mesenteric arteries. 18 To evaluate whether intracellular Ang II modifies nifedipine-insensitive Ca 2ϩ channel currents, intracellular Ang II action was evaluated in the presence of 10 mol/L nifedipine in the bath solution. The nifedipine-insensitive current was not enhanced by the intracellular dialysis of 10 nmol/L Ang II (at 10 minutes, 103Ϯ7% of the control [nϭ7]). These results suggest that administered Ang II enhances primarily L-type Ca 2ϩ channels. To determine which receptor subtype is involved with the Ang II action, CV-11974 (1 mol/L), an Ang II type 1 (AT 1 ) receptor antagonist, or PD123319 (1 mol/L), an Ang II type 2 (AT 2 ) receptor antagonist, was administered with Ang II (10 nmol/L) in the pipette solution. CV-11974, but not PD123319, inhibited the Ang II action (Figure 2 ). In the next experiment, to exclude the possibility that intracellular Ang II leaks from the cell and acts on the surface membrane AT 1 receptor, CV-11974 (1 mol/L) was applied to the bath solution. The Ang II action was not affected by the bath application of CV-11974 (Figure 2 
Discussion
In the present study, we demonstrated for the first time that Ang II administered intracellularly stimulates voltageoperated Ca 2ϩ channels in vascular smooth muscle cells. Our findings are in good agreement with previous observations that intracellular administration of Ang II increases intracellular Ca 2ϩ concentration of smooth muscle and causes contraction via an extracellular Ca 2ϩ -dependent mechanism. 13,14 The intracellular AT 1 receptor antagonist inhibited the intracellular Ang II action, but the intracellular AT 2 receptor antagonist and the extracellular AT 1 receptor antagonist did not affect the intracellular Ang II action. Thus, intracellular Ang II enhances Ca 2ϩ channel current via intracellular Ang II-binding sites similar to the AT 1 receptor. In cultured rat aortic muscle cells, an injection of Ang II increased the cytosolic Ca 2ϩ levels. 13 This Ang II action was inhibited by intracellular administration of the AT 1 receptor antagonist, whereas the AT 2 receptor antagonist was not examined. In the rat aorta, an intracellular administration of Ang II caused contraction. 14 A concomitant application of the AT 1 receptor antagonist inhibited this contraction, although the AT 2 receptor antagonist also inhibited the Ang II action with a weaker potency. The high sensitivity to the AT 1 receptor antagonist in those previous studies is in good agreement with our present observations. Because the AT 2 receptor antagonist did not affect the intracellular Ang II action in the present study, species and/or regional differences might exist.
Ang II has been shown to exist in the submembrane vesicle-like structure (endosome/lysosome) and in the nuclei of vascular smooth muscle cells. 3, 13, 19, 20 In addition, Haller et al 13 have shown that after microinjection of Ang II into the cell, Ang II spreads throughout the cytosol and is then distributed in submembrane lysosomes and nuclei in cultured aortic muscle cells. Thus, it is possible that intracellular Ang II binding sites, which are responsible for the present results, can be located in submembrane lysosomes or nuclei.
It has not been clarified what type of Ang II-binding sites are involved in the intracellular Ang II action in the present study. A soluble Ang II-binding protein was reported first in the liver and then in various tissues, including vascular tissues. 6 -8 This protein has no significant homology with the plasma membrane AT 1 receptor and does not bind to losartan, an AT 1 receptor antagonist. Because the AT 1 receptor antagonist was effective in the present study, it is unlikely that this protein is involved. It has also been reported that Ang II-binding sites exist on nuclear membranes, which are sensitive to the AT 1 receptor. 9 -11 Because intracellular Ang II action appeared within several minutes of administration in the present study, nucleus receptors regulating gene transcription may not be involved. Another possible Ang II-binding site is the internalized AT 1 receptor. 3, 19, 20 Binding of Ang II to the AT 1 receptor causes a rapid internalization of the receptor in various cell types, including vascular smooth muscle cells. Because the internalized receptors exist in endosomes/lysosomes, it could be speculated that intracellularly administered Ang II is distributed to lysosomes and binds to the internalized AT 1 receptors.
In vascular smooth muscle cells, agonists that stimulate phospholipase C, including Ang II and norepinephrine, enhance L-type Ca 2ϩ channel current. [21] [22] [23] The stimulatory action is explained, in most studies, by the activation of PKC. Stimulation of cAMP-dependent protein kinase also enhances L-type Ca 2ϩ channel currents; however, in some conditions, such stimulation inhibits or does not affect L-type Ca 2ϩ channel currents. 22, 23 In the present study, an inhibition of cAMP-dependent protein kinase by KT5720 did not affect the L-type Ca 2ϩ channel currents, but that of phospholipase C (U-73122) or PKC (calphostin C and PKC inhibitory peptide) inhibited the intracellular Ang II action. Thus, an activation of phospholipase C and PKC is likely to be involved in the intracellular action of Ang II. It is interesting that internalization of the AT 1 receptor with Ang II appears to be essential to the full expression of Ang II action in vascular smooth muscle, which includes the sustained activation of PKC. 19, 24, 25 Another possible pathway is through the activation of tyrosine kinase 26 ; however, information about the role of tyrosine kinase on the regulation of Ca 2ϩ channels in smooth muscle cells has not been accumulated.
Although endocytosis or internalization is an important source of intracellular Ang II in vascular muscle cells, 3, 19, 20, 26 Ang II is also considered to be generated inside the cells. Components required for Ang II generation, such as angiotensinogen, renin, and ACE, have been shown to exist in the cell. 1, 2, 4 In the present study, an intracellular administration of Ang I stimulated the Ca 2ϩ channel current; this stimulation was inhibited by enalaprilat and CV-11974. Our observation suggested that ACE activity exists in the cytosol and plays an essential role in converting Ang I to Ang II. Ang II but not Ang I acts on the intracellular Ang II-binding sites. Although Ang II-generating enzymes including chymase do play a role in various tissues, 27 their contribution may be limited in guinea pig vascular smooth muscle cells. These results are in contrast to the observation of Brailoiu et al 14 that captopril failed to inhibit the intracellular Ang I action on contraction of the aorta. The reason for this discrepancy is not known at present.
The present study showed that intracellular Ang II concentrations of Ն1 nmol/L were effective in enhancing the Ca 2ϩ channel currents. These concentrations are nearly the same as those reported to be necessary for stimulating Ca 2ϩ influx in cultured aortic muscle cells and contraction of the aorta. 13, 14 It has been also shown that tissue concentrations of Ang II become higher than plasma concentrations after AT 1 receptor-dependent internalization in the kidney and adrenal tissues. 28 Thus, the concentrations examined in the present study could be sufficient to stimulate Ca 2ϩ channels in the physiological condition. In the present study, a dose-response relationship for the intracellular Ang II action was not apparent. Although the reason for this is not known, it is possible that a slow diffusion of Ang II from the pipette to the cytosol and accumulation of Ang II inside the cell may mask the dose-response relationship.
In summary, we have demonstrated that intracellular administration of Ang II and Ang I enhances L-type Ca 2ϩ channel currents. Ang I could be converted to Ang II by ACE and affect Ca 2ϩ channels. Our observation also suggests that intracellular binding sites similar to the AT 1 receptor, which is associated with phospholipase C and PKC, are involved in the intracellular Ang II action.
